Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2006-11-20
pubmed:abstractText
Exogenous doses of 60 mg/kg alpha(1)-antitrypsin (AAT) every 7 days are recommended in patients with severe AAT deficiency. However, long term administration of weekly doses is not well accepted by patients. Using pharmacokinetic simulations, we evaluated whether steady state minimum concentrations of total AAT can be maintained above the threshold of 0.5 g/l with longer intervals between doses.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/16928711-10556107, http://linkedlifedata.com/resource/pubmed/commentcorrection/16928711-11243952, http://linkedlifedata.com/resource/pubmed/commentcorrection/16928711-11377114, http://linkedlifedata.com/resource/pubmed/commentcorrection/16928711-12045122, http://linkedlifedata.com/resource/pubmed/commentcorrection/16928711-12426287, http://linkedlifedata.com/resource/pubmed/commentcorrection/16928711-12728289, http://linkedlifedata.com/resource/pubmed/commentcorrection/16928711-12740257, http://linkedlifedata.com/resource/pubmed/commentcorrection/16928711-12853554, http://linkedlifedata.com/resource/pubmed/commentcorrection/16928711-14522813, http://linkedlifedata.com/resource/pubmed/commentcorrection/16928711-1511530, http://linkedlifedata.com/resource/pubmed/commentcorrection/16928711-16827978, http://linkedlifedata.com/resource/pubmed/commentcorrection/16928711-17114371, http://linkedlifedata.com/resource/pubmed/commentcorrection/16928711-2787611, http://linkedlifedata.com/resource/pubmed/commentcorrection/16928711-3261353, http://linkedlifedata.com/resource/pubmed/commentcorrection/16928711-3264124, http://linkedlifedata.com/resource/pubmed/commentcorrection/16928711-3493719, http://linkedlifedata.com/resource/pubmed/commentcorrection/16928711-3494198, http://linkedlifedata.com/resource/pubmed/commentcorrection/16928711-7842193, http://linkedlifedata.com/resource/pubmed/commentcorrection/16928711-8181327, http://linkedlifedata.com/resource/pubmed/commentcorrection/16928711-8520756, http://linkedlifedata.com/resource/pubmed/commentcorrection/16928711-9044469, http://linkedlifedata.com/resource/pubmed/commentcorrection/16928711-9315791, http://linkedlifedata.com/resource/pubmed/commentcorrection/16928711-9551749, http://linkedlifedata.com/resource/pubmed/commentcorrection/16928711-9926146
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0040-6376
pubmed:author
pubmed:issnType
Print
pubmed:volume
61
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1059-64
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Alpha-1-antitrypsin deficiency: optimal therapeutic regimen based on population pharmacokinetics.
pubmed:affiliation
Pharmacy Service, Hospital Clínic, (IDIBAPS), Barcelona, Spain.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't